Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND

Written by Guest User

Apr. 16
2018

VANCOUVER, British Columbia and SAN DIEGO, April 16, 2018 - Phoenix Molecular Designs have entered into a collaboration with STA Pharmaceutical Co., Ltd (STA), a WuXi AppTec group company, to manufacture the PMD-026 needed for IND-enabling toxicology studies and a Phase I study.

Read the full press release here

Guest User
Previous

PhoenixMD team meet in San Diego for first IND planning meeting
Next

Phoenix Molecular Designs team members meet with investors to discuss partnership opportunities at premier Life Science events in the US.